Serum CC-16 level is associated with asymptomatic airway responsiveness in adults from the EGEA study

Marta Rava, PhD\textsuperscript{1,2}, Nicole Le Moual, PhD\textsuperscript{1,2}, Xavier Dumont\textsuperscript{3}, Stefano Guerra\textsuperscript{4,5}, Valerie Siroux\textsuperscript{6,7,8}, Beno	extit{	extipa{i}tic} Jacquemin\textsuperscript{1,2,4}, Francine Kauffmann\textsuperscript{1,2}, Alfred Bernard\textsuperscript{3}, Rachel Nadif\textsuperscript{4,2}

1. INSERM, VIMA: Aging and chronic diseases. Epidemiological and public health approaches, U1168, F-94807, Villejuif, France
2. Univ. Versailles St-Quentin-en-Yvelines, UMR-S 1168, France
3. Louvain Centre for Toxicology and Applied Pharmacology (LTAP), Catholic University of Louvain, Tour Pasteur, avenue E. Mounier, 53- box B1-52-12, 1200 Brussels, Belgium
4. Centre for Research in Environmental Epidemiology (CREAL), IMIM-Hospital del Mar, CIBERESP, Carrer del Doctor Aiguader, 88, 08003 Barcelona
5. Arizona Respiratory Center, University of Arizona, 1501 N. Campbell Ave., Suite 2349, PO Box 245030 Tucson, AZ
7. INSERM, IAB, Team of Environmental Epidemiology applied to Reproduction and Respiratory Health, F-38000 Grenoble, France.
8. CHU de Grenoble, IAB, Team of Environmental Epidemiology applied to Reproduction and Respiratory Health, F-38000 Grenoble, France.
9. INSERM, U823, Institut Albert Bonniot, Rond-point de la Chantourne, 38706 La Tronche, France

Corresponding author:

Marta RAVA, PhD
Current contact information:

Genetic & Molecular Epidemiology Group
Human Cancer Genetics Program
Spanish National Cancer Research Centre -
Centro Nacional de Investigaciones Oncológicas (CNIO)
Melchor Fernández Almagro, 3
28029-Madrid, Spain
Tel +34 912246900 (3332)
Fax +34 912246980
E-mail: mrava@cnio.es

MR, RN, NLM, BJ, FK and VS participated in study design and data collection. AB and XD performed the measurement. MR, NLM, FK, SG and VS interpreted the data. MR and RN drafted the manuscript with input from the other authors. All the authors revised the article critically for important intellectual content and approved the final manuscript.

Abstract’s words count: 248

**Manuscript’s words count: 2500**
Summary at a glance (less than 50 words)

We evaluated the association between serum level of CC-16 and asthma, lung function and airway responsiveness and showed that decreased serum CC-16 level is associated with decreased lung function and higher airway responsiveness in participants without asthma.

Abstract

Background and objective

Club cell secretory protein (CC-16) is a sensitive biomarker of airways epithelium integrity and because of its presumed relationship to inflammation, has gained increasing interest as biological marker in the study of chronic pulmonary diseases. Nevertheless little evidence exists of an association between CC-16 serum levels and asthma, lung function and airway responsiveness.

Methods

Serum CC-16 level was determined by latex immunoassay in 1298 participants from the French Epidemiological case-control and family-based study on Genetics and Environment of Asthma (EGEA) (mean age 43 years; 49% men, 38% with asthma). Pre-bronchodilator lung function (Forced Expiratory Volume in one second (FEV₁), Forced Vital Capacity (FVC) and FEV₁/FVC) and degree of airway responsiveness, expressed as a function of the dose-response slope to methacholine test were measured. Standardized residuals (CC-16 z-score) obtained by regressing CC-16 level on the glomerular filtration rate were studied in association with asthma, lung function and airway responsiveness in participants with and without asthma.

Results

CC-16 geometric mean level was 12.4 µg/L (range: 2.2 - 70.6 µg/L). In participants without asthma, lower CC-16 z-score was associated with impaired FEV₁/FVC% (beta=0.50 (95%CI: 0.06, 0.95) and with higher degree of airway responsiveness (beta=0.24 (95%CI: 0.09, 0.39)).
CC-16 was not associated with impaired lung function or airway responsiveness in participant with asthma.

Conclusions

Lower CC-16 serum level was associated with impaired lung function and higher degree of airway responsiveness, suggesting that serum CC-16 level may reflect early damages of the lung epithelium integrity in adults without asthma.

Keywords

Uteroglobin; asthma; lung function test; airway hyper-reactivity; biological marker

Short title

CC-16 level and airway responsiveness
INTRODUCTION

Club cell protein (CC-16, also called CC10, SCGB1A1 or CCSP) is mainly secreted by the club cells along the tracheobronchial tree, diffuses passively into the bloodstream, and is finally rapidly eliminated by glomerular filtration. While the exact function of CC-16 is not known, it is suggested to be a protective mediator in the airway inflammatory process and to have protective effects from oxidative stress on the respiratory tract. Serum CC-16 level is considered as a sensitive biomarker of airways epithelium integrity, transiently increasing following acute exposure to pulmonary irritants and decreasing after chronic exposures associated with an impairment or reduction of club cells. Overall the assay of CC-16 is a sensitive test to allow the detection of early damage to the respiratory epithelium and because of its presumed relationship to inflammation, CC-16 has gained increasing interest as a biological marker in the study of chronic pulmonary diseases.

Asthma is a chronic inflammatory disorder of the airways characterised by increased airway responsiveness (AR) and associated with accelerate decline in lung function. Although AR is a key characteristic of asthma, it may occur without asthma-like symptoms or previous diagnosis of asthma, which is called asymptomatic AR.

Findings on the association between CC-16 and asthma are conflicting. No association with asthma was observed in adults from a large cross-sectional study, while a negative association was observed in participants with asthma in clinical studies. Only few large epidemiological studies evaluated the association between CC-16 level and lung function, providing evidence of a negative association. A negative association between serum CC-16 level and AR was described only in one cross-sectional study, and no study evaluated the specific association with asymptomatic AR. Overall there is a lack of large epidemiological studies considering together the relations of serum CC-16 with asthma, lung function and AR. Our hypothesis is that serum level of CC-16 decreases in participants with...
asthma, impaired lung function and airway responsiveness. The aim of the present paper is to study the associations between serum CC-16 levels and asthma, impaired lung function and airway responsiveness in the French epidemiological study on the genetics and environment of asthma (EGEA) whom participants with or without asthma have been extensively characterized regarding respiratory phenotypes and lung function tests.

METHODS

Study population

EGEA is a cohort study based on an initial group of asthma cases, their first-degree relatives, and controls (first survey, n=2047)\(^16\). At the second survey\(^17\), detailed phenotyping was performed with lung function tests including methacholine challenge (see Figure 1 and the online supplemental population and protocol section). This analysis is based on participants who were adults at the second survey (≥ 16 years old, n=1570 adults) with available data on asthma, serum CC-16 level and who did not smoke 1 hour before the examination (N=1298).

Biological phenotypes

Serum CC-16 level was determined with latex immunoassay using a rabbit anti-CC-16 antibody (Dakopatts, Glostrup, Denmark)\(^18\) and purified CC-16 protein as standards (see the online supplemental biological phenotypes section).

Serum creatinine was determined with standard traceable IDMS (isotope dilution mass spectrometry traceable) assay and its clearance was calculated by the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula\(^19\) which depends on sex and age of participants.

Clinical phenotypes
Asthma and asthma related phenotypes

Current asthma referred to the report of asthma attacks or asthma treatment or asthma-like symptoms in the past 12 months. Participants without current asthma and that never reported ever asthma were considered as controls. Based on five asthma symptoms over the past 12 months (wheezy breathlessness, woken up by chest tightness and by an attack of shortness of breath, attack of shortness of breath at rest and after exercise), the asthma symptom score was computed, as previously proposed.

Asthma control was assessed from survey questions and lung function, closely adapted from the 2006-2009 Global Initiative for Asthma guidelines 2006, as previously described in (see online supplemental population and protocol section for more details).

Pulmonary function

Pulmonary function test was performed using a standardized protocol with similar equipment across centres according to the ATS/ERS guidelines. FEV₁ and FVC percent predicted values were based on Stanojevic et al. reference equations.

Airway responsiveness

Methacholine bronchial challenge test was performed in participants with no medical contraindication, unless baseline FEV₁<80% predicted or FEV₁ post dilution was lower than 90% of the baseline FEV₁, following the same protocol the European Community Respiratory Health Survey (ECRHS). Airway hyper-responsiveness (AHR) was defined as a 20% fall in FEV₁ from the highest FEV₁ postdiluent (PD₂₀) during the test with an accumulated dose of methacholine. “High AHR” refers to a PD₂₀ related to an accumulated methacholine dose of 1 mg (PD₂₀ ≤1mg) and “any AHR” refers to a PD₂₀ ≤4 mg.

The degree of airway responsiveness was quantified by a transformed dose-response slope obtained regressing the percentage fall in FEV₁ on log₁₀ methacholine dose. Low values of
slopes correspond to high degree of bronchial responsiveness. We referred to participants without asthma but with airway responsiveness as “asymptomatic AR”.

**Ethics Statement**

Ethical approval was obtained from the relevant institutional review board committees at Cochin Port-Royal Hospital and Necker-Enfants Malades Hospital, Paris. Written informed consent was signed by kin or guardians of the minors/children and all other adult participants.

**Statistical analyses**

Since CC-16 level strongly depends on glomerular filtration rate (eGFR) level (Table 1), we obtained eGFR-adjusted residuals by regressing log-transformed CC-16 on eGFR and used the standardized residuals (CC-16 z-score, Mean= 0, SD=1) in the subsequent analysis as independent variable. Association between CC-16 and asthma was estimated with a logistic regression model. Since the expression of CC-16 is known to be inducible by corticosteroids, association with asthma was repeated after excluding participants who used inhaled corticosteroids during the previous 12 months (n=265). To account for the specific design of the EGEA study analyses on lung function and AR were conducted separately in participant with and without asthma and estimates were obtained with linear or logistic regression model, where appropriate. All parameters were estimated with generalized estimating equations (GEE) with an exchangeable working correlation to account for the potential clustering within the families. Estimates were adjusted for sex, smoking status and pack-years, age and height when needed. Since CC-16 has shown a time-dependent daily variation, blood sampling time (range 7 – 20h) was included as covariate. Further, to test whether the association between CC-16 and AR was independent from the bronchial calibre of participants, the level of FEV$_1$% predicted was added as a covariate in the multivariate model. Finally, since tobacco smoke is associated with decreased level of CC-16, as well as with impaired lung function
and increased AR, the analyses were stratified by smoking status. All statistical analyses were performed using R version 2.14.28

RESULTS

Characteristics of the sample (Table 1)
The study population included 1298 participants with a mean age of 43 years (range 16–80 years). Lung function test was performed by 1278 participants: among them 416 did not perform the methacholine test because of poor lung function (n=113) or other reasons (n=303) and data on AR were available for 862 participants (see online result section for more details).

CC-16 Serum level
Overall, serum CC-16 geometric mean (GM) level was 12.4 µg/L, ranging from 2.2 to 70.6µg/L (Table 1). CC-16 level was higher in men, increased with age, decreased in smokers and with pack-years smoked decreased with blood sampling time and was negatively correlated with eGFR (Table 2). After adjustment for eGFR and blood sampling time, the negative associations with age and smoking were confirmed only in participants without asthma (beta=-0.04, p=0.06 and beta for trend=-0.08, p=0.006, respectively).

Associations between CC-16 and asthma
Univariate association between CC-16 level and current asthma (as reported in Table 1) was no longer confirmed after adjustment for eGFR (beta = 0.88 (95%CI 0.74, 1.05)) and when eGFR adjusted CC-16 z-score was considered as predictive variable (OR_adj=0.92 (95%CI: 0.82, 1.02)). No association was observed between CC-16 z-score and asthma in participants not treated by inhaled corticosteroids (n=265, OR_adj=0.94 (95%CI 0.82, 1.09)), nor by oral corticosteroids or anti-leukotriene (alone or combined, data not shown).
In participants with asthma, no association was observed between CC-16 z-score and asthma
control (p>0.10) or asthma score (p=0.08 for score≥2) and CC-16 levels did not vary with ICS use (GM=11.7 (95%CI 8.03, 15.4) µg/L and GM=11.9 (95%CI 8.35, 15.5) µg/L, p =0.16, in participants no-ICS and ICS users respectively).

**Associations between CC-16 and lung function**

In participants with asthma, no association was observed between CC-16 and lung function (table E1, online), and this result was confirmed also in non-ICS users (n=253, p=0.10).

In participants without asthma (Table 3), reduced FEV₁% predicted (borderline significant) and FEV₁/FVC were associated with reduced CC-16 z-score, considered both on a continuous scale and categorized into quartiles (Figure E1, online). Association with lung function was higher in current smokers than in never smokers (Figure 2E, online), with statistically significant interactions for FEV₁% predicted and FEV₁/FVC.

**Associations between CC-16 and AR**

CC-16 GM level decreased from 12.2 (95%CI: 11.7, 12.7) µg/L in participants who performed the methacholine challenge test (N=862) to 11.1 (95%CI 9.75, 12.5) µg/L in 113 participants who did not performed the test because of poor lung function.

In participants with asthma no association was observed between CC-16 z-score and AR (table E1 online), and this result was confirmed also in non-ICS users.

In participants without asthma lower CC-16 level was associated with lower level in the dose-response slope (Figure 2a) borderline higher risk of any AHR (PD20≤4mg) and high AHR (PD_{20}≤1mg) (Table 3). These results were confirmed also when FEV₁% predicted was included in the multivariate model (beta for the slope: 0.20 (95%CI: 0.05, 0.35)) and when only participants without any asthma symptom (asthma score<2) were considered (n=465, beta for the slope =0.23 (95%CI 0.07, 0.39)). Similar results were observed when CC-16 z-score was grouped in quartiles (Figure E1, online). Participants in the highest CC-16 z-score
quartile were associated with lower slope ($\beta_{adj} = 0.50$ (95%CI: 0.08, 0.92)) and a lower risk of high AHR ($OR_{adj} = 0.30$ (95%CI: 0.12, 0.75)) than participants in the lowest CC-16 z-score quartile.

Interaction between smoking and CC-16 z-score was statistically significant for the slope ($p=0.02$) (Figure 2E online). After adjustment for covariates, lower CC-16 z-score was associated with lower slope both in current as well as in ex-smokers ($\beta_{adj} = 0.50$ (95%CI: 0.21, 0.79), $\beta_{adj} = 0.24$ (95%CI: 0.01, 0.46), respectively).

**DISCUSSION**

Using data from a large epidemiological study on asthma, we observed that reduced lung function and higher AR were associated with decreased CC-16 level only in participants without asthma. No significant association was observed between CC-16 level and current asthma.

The major assets of this study are the sample size, the standardization of the sample collection and the availability of clinical parameters. Definition of asthma case is precise leading to a very limited risk of false positives. Serum CC-16 level were similar to the reference values in healthy non-smokers (between 10 and 15 $\mu$g/L on average). Prevalence of airway hyper-responsiveness, measured by a methacholine challenge test was quite high in participants without asthma. A possible explanation is that part of the participants without asthma is first degree relatives of asthma cases. Nevertheless, this result is consistent with the relatively considerable number of asymptomatic participants with AHR reported in cross-sectional epidemiologic studies, ranging from 19.3 to 62.4%.

CC-16 level was standardized on eGFR so that all the associations were not affected by eGFR’s sex and age-related variation. CC-16 decreased with smoking and pack-years smoked, varied with blood sampling time and was negatively associated with eGFR, consistent with previously published results. However, with a cross-sectional approach,
causal association between CC-16 and respiratory diseases could not be established.

We found no association between CC-16 level and asthma. Similarly, no association was observed with asthma in 859 participants to population-based multi-centre ECRHS \(^{10}\) neither with asthma and bronchitis in 6531 men aged 67–77 year from a cross-sectional study \(^{32}\). To date, most evidence of an association between CC-16 and asthma comes from small (less than 100 participants) clinical studies, both in children \(^{33, 34}\) and in adults \(^{11, 12}\). A possible explanation for this apparent discrepancy is that participants from clinical studies are more likely to have severe asthma than participants from population-based studies. Further, clinical samples are known to be vulnerable to selection bias that may compromise the generalizability of findings.

We found that FEV\(_1\) and FEV\(_1\)/FVC were associated with serum CC-16 level only in participants without asthma. Previously, a positive association between serum CC-16 and FEV\(_1\) and FVC was observed by in 402 fire-fighters from a cross-sectional study \(^{14}\) and with FEV\(_1\)% predicted and FEV\(_1\)/FVC ratio in adults from the general population in the ECHRS study \(^{10}\), after adjustment for the same large range of covariates, including blood sampling time. The association between lung function parameters and CC-16 found in our study is consistent with previous published results on an association between lung function and markers of inflammation, such as C-Reactive Protein \(^{35}\).

We observed a negative association between CC-16 level and AR in adults without asthma that was confirmed in participants without any asthmatic symptom and was also independent from bronchial calibre. To the best of our knowledge this is the first study showing an association between CC-16 and asymptomatic AR. Previously, a negative association between AR and CC-16, apparently unnoticed by the authors, was observed in 4724 smokers with mild to moderate airflow limitation from the Lung Health Study \(^{13}\) and in 402 fire-fighters, after adjustment for smoking and atopic status \(^{14}\). These findings may be related to mild inflammatory changes, that are present in airway mucosa of patients with AHR \(^{36}\) that may
lead to damages of airway epithelium and consequent decreased number of club cells in small airways. Alternatively, genetically determined lower level of CC-16 and subsequent fragile epithelium may contribute to the development of asymptomatic AHR. In such case, methacholine or any other bronchoconstrictive substance may easily penetrate the lung epithelium and induce bronchial hyperreactivity. This hypothesis is supported by the findings of Taniguchi and colleagues, that showed that the A38G polymorphism in the CC-16 gene was associated with both plasma CC-16 level and AR in 154 asymptomatic, young, healthy adults. In the EGEA study, we previously found that methacholine AHR was significantly related to asthma incidence in asymptomatic participants. It could be postulated that asymptomatic AR might precede development of respiratory symptoms and asthma through mechanisms related with airway inflammation, damage to epithelium integrity and structural changes in the airway mucosa that are associated with decreased CC-16 levels in the airway. Future longitudinal studies, especially on paediatric population, will be useful to evaluate the role of CC-16 as a prognostic marker for asthma.

The lack of association between CC-16 level and lung function or AR in asthmatic group could be partly explained by the complex mechanisms, including inflammation and oxidative stress that characterizes this disease, leading to less variability of CC-16 level in participants with asthma and less sensitivity to variation in AR. Further, the differential association between CC-16 and lung function and AR between participants without and with asthma support the evidence of heterogeneity of AR in asymptomatic and symptomatic participants.

In conclusion, we observed that decreased CC-16 serum level were associated with asymptomatic airway responsiveness and impaired lung function, only in participants without asthma. Those results suggested that serum level of CC-16 may help detecting early damages of the lung epithelium integrity. Further longitudinal studies will help in understanding whether this information will be used for early detecting asthmatic trait.
**Funding:** Research funded by the European Respiratory Society (Fellowship LTRF fellowship n°123-2011) and the NETA project (French Agency of Health Safety, Environment and Work (AFSSET, EST-09-15).

**Acknowledgments**

The authors thank all those who participated in the study and in the various aspects of the examinations and all those who supervised the study in all centers. The authors are grateful to the three CIC-Inserm units of Necker, Grenoble and Marseille which supported the study and where subjects were examined. They are also grateful to the three biobanks in Lille (CIC-Inserm), Evry (Centre National de Genotypage) and Annemasse (Etablissement francais du sang) where biological samples are stored. They are indebted to all the individuals who participated, without whom the study would not have been possible.

**EGEA cooperative group**

**Coordination:** V Siroux (epidemiology, PI since 2013); F Demenais (genetics); I Pin (clinical aspects); R Nadif (biology); F Kauffmann (PI 1992-2012).

**Respiratory epidemiology:** Inserm U 700, Paris: M Korobaeff (Egea1), F Neukirch (Egea1); Inserm U 707, Paris: I Annesi-Maesano (Egea1-2); Inserm CESP/U 1018, Villejuif: F Kauffmann, N Le Moual, R Nadif, MP Orlyszczyn (Egea1-2), R Varraso; Inserm U 823, Grenoble: V Siroux.

**Genetics:** Inserm U 393, Paris: J Feingold; Inserm U 946, Paris: E Bouzigon, F Demenais, MH Dizier; CNG, Evry: I Gut (now CNAG, Barcelona, Spain), M Lathrop (now Univ McGill, Montreal, Canada).

**Clinical centers:** Grenoble: I Pin, C Pison; Lyon: D Ecochard (Egea1), F Gormand, Y Pacheco; Marseille: D Charpin (Egea1), D Vervloet (Egea1-2); Montpellier: J Bousquet; Paris Cochin: A Lockhart (Egea1), R Matran (now in Lille); Paris Necker: E Paty (Egea1-2), P Scheinmann (Egea1-2); Paris-Trousseau: A Grimfeld (Egea1-2), J Just.
**Data and quality management:** Inserm ex-U155 (Egea1): J Hochez; Inserm CESP/U 1018, Villejuif: N Le Moual; Inserm ex-U780: C Ravault (Egea1-2); Inserm ex-U794: N Chateigner (Egea1-2); Grenoble: J Quentin-Ferran (Egea1-2).

REFERENCES


2501.


31. Gioldassi XM, Papadimitriou H, Mikraki V, Karamanos NK. Clara cell secretory


REFERENCES (final version)


23


Table 1: Socio-demographic and clinical characteristics of the participants

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>All</th>
<th>Without asthma</th>
<th>With asthma</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>1298</td>
<td>803</td>
<td>495</td>
<td></td>
</tr>
<tr>
<td>Females, %</td>
<td>51.4</td>
<td>53.4</td>
<td>48.1</td>
<td>0.07</td>
</tr>
<tr>
<td>Age, mean (SD), years</td>
<td>43.8 (16.4)</td>
<td>46.4 (15.8)</td>
<td>39.6 (16.5)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Smoking status and intensity, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lifetime non-smoker</td>
<td>50.1</td>
<td>50.9</td>
<td>48.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Ex-smoker, &lt;15 pack-years</td>
<td>19.2</td>
<td>20.2</td>
<td>17.5</td>
<td></td>
</tr>
<tr>
<td>Ex-smoker, ≥15 pack-years</td>
<td>8.31</td>
<td>8.53</td>
<td>7.94</td>
<td></td>
</tr>
<tr>
<td>Smoker, &lt;15 pack-years</td>
<td>16.5</td>
<td>12.9</td>
<td>22.4</td>
<td></td>
</tr>
<tr>
<td>Smoker, ≥15 pack-years</td>
<td>5.9</td>
<td>7.4</td>
<td>3.46</td>
<td></td>
</tr>
<tr>
<td>Asthma symptom score</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>13.1</td>
<td>7.33</td>
<td>22.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>1</td>
<td>86.9</td>
<td>92.7</td>
<td>77.6</td>
<td></td>
</tr>
<tr>
<td>≥2</td>
<td>32.9</td>
<td>63.3</td>
<td>9.78</td>
<td></td>
</tr>
<tr>
<td>Lung function test, N</td>
<td>1278</td>
<td>791</td>
<td>487</td>
<td></td>
</tr>
<tr>
<td>FEV1 % predicted*, Mean (SD)</td>
<td>97.0 (17.1)</td>
<td>100.8 (15.2)</td>
<td>90.8 (18.2)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FVC% predicted*, Mean (SD)</td>
<td>99.7 (14.7)</td>
<td>100.8 (14.5)</td>
<td>98.0 (14.8)</td>
<td>0.001</td>
</tr>
<tr>
<td>FEV1/FVC, Mean (SD)</td>
<td>77.9 (9.32)</td>
<td>79.8 (7.37)</td>
<td>74.9 (11.2)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FEV1 %predicted*≥80%, %</td>
<td>86.9</td>
<td>92.7</td>
<td>77.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Methacholine</td>
<td>862</td>
<td>540</td>
<td>322</td>
<td></td>
</tr>
<tr>
<td>challenge test, N</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dose-response slope,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N, Mean (SD)</td>
<td>827, 6.34 (2.03)</td>
<td>527, 6.95 (1.81)</td>
<td>300, 5.27 (1.96)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Any AHR (PD20≤4mg), N</td>
<td>800</td>
<td>514</td>
<td>286</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Any AHR (PD20≤4mg), N (%)</td>
<td>High AHR (PD20≤1mg), N (%)</td>
<td>High AHR (PD20≤1mg), N(%)</td>
<td>Inhaled corticosteroid use, %</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>---------------------------</td>
<td>-----------------------------</td>
<td>---------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td></td>
<td>339</td>
<td>815</td>
<td>67</td>
<td>20.5</td>
</tr>
<tr>
<td></td>
<td>138 (26.8)</td>
<td>523</td>
<td>67 (12.8)</td>
<td>3.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>201 (70.3)</td>
<td>48.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AR: Airway responsiveness; AHR: Airway Hyper-responsiveness; CC-16: Club cell secretory protein; FEV₁: forced expiratory volume in 1 second; FVC: forced vital capacity; GFR: Glomerular Filtration Rate; GM: Geometric Mean; PD₂₀: 20% reduction in FEV₁ after methacholine challenge test (1 mg or 4 mg cumulative dose); SD: Standard Deviation; 

*Stanojevic reference equations.
Table 2. Association between participants’ characteristics and CC-16 level

<table>
<thead>
<tr>
<th></th>
<th>Non asthmatics (N=803)</th>
<th>Asthmatics (N=495)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N CC-16 GM / Beta (95%CI)†</td>
<td>N CC-16 GM / Beta (95%CI)†</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>374 13.1 (12.3,13.9)</td>
<td>257 12.4 (11.5,13.3)*</td>
</tr>
<tr>
<td>Females</td>
<td>429 12.5 (11.8,13.3)</td>
<td>-0.03 238 11.2 (10.4,12.1) -0.10**</td>
</tr>
<tr>
<td>Age, 10 years</td>
<td>0.05 (0.02, 0.08)***</td>
<td>-0.05** 0.07 (0.04, 0.10)*** 0.02</td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lifetime non-smoker</td>
<td>406 13.1 (12.3,13.9) **</td>
<td>-0.04** 239 11.6 (10.7,12.5)* -0.01</td>
</tr>
<tr>
<td>Ex smoker, &lt;15 pack-years</td>
<td>179 13.8 (12.6,15.0)</td>
<td>102 13.3 (11.8,15.0)</td>
</tr>
<tr>
<td>Ex-smoker, &gt;15 pack-years</td>
<td>50 12.0 (9.78,14.7)</td>
<td>23 13.0 (10.2,16.6)</td>
</tr>
<tr>
<td>Smoker, &lt;15 pack-years</td>
<td>123 12.1 (10.8,13.6)</td>
<td>115 11.1 (9.93,12.5)</td>
</tr>
<tr>
<td>Smoker, &gt;15 pack-years</td>
<td>39 9.34 (7.61,11.5)</td>
<td>12 8.99 (5.77,14.0)</td>
</tr>
<tr>
<td>Blood sampling time, hour</td>
<td>801 -0.03 (-0.05, -0.008)***</td>
<td>492 -0.04 (-0.07, -0.02)*** -0.05***</td>
</tr>
<tr>
<td>Serum creatinine, mg/dL</td>
<td>803 0.79 (0.55, 1.03)***</td>
<td>495 0.48 (0.16, 0.79)**</td>
</tr>
<tr>
<td>eGFR estimated, mL/min*1.73m²</td>
<td>803 -0.008 (-0.01, -0.006)***</td>
<td>495 -0.006 (-0.009, -0.003)*** -0.01**</td>
</tr>
</tbody>
</table>
CC-16: Club cell secretory protein; CI: Confidence Interval; eGFR: Glomerular Filtration Rate; GM: Geometric Mean;

† Overall P-values for the association between each participant characteristic and CC-16 level

‡ Beta coefficients and p-values from one multivariate regression model with sex, age, smoking status (test for trend), sampling time and glomerular filtration rates as covariates and CC-16 z-score as outcome variable

*p<.10, ** p<.05, *** p<.001.
Table 3. Association between airway responsiveness and lung function and GFR-standardized CC-16 z-score in participants without asthma

<table>
<thead>
<tr>
<th></th>
<th>N</th>
<th>Unadjusted beta/ OR (95%CI)</th>
<th>p</th>
<th>Adjusted beta/ OR (95%CI)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Lung function measurements</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV&lt;sub&gt;1&lt;/sub&gt; % pred. Values*†</td>
<td>791</td>
<td>1.15 (0.05,2.24)</td>
<td>0.04</td>
<td>1.01 (-0.07,2.08)</td>
<td>0.07</td>
</tr>
<tr>
<td>FVC % pred. Values*‡</td>
<td>791</td>
<td>0.57 (-0.45,1.60)</td>
<td>0.27</td>
<td>0.42 (-0.61,1.45)</td>
<td>0.43</td>
</tr>
<tr>
<td>FEV&lt;sub&gt;1&lt;/sub&gt;/FVC‡</td>
<td>762</td>
<td>0.62 (0.12,1.12)</td>
<td>0.02</td>
<td>0.50 (0.06,0.95)</td>
<td>0.02</td>
</tr>
<tr>
<td><strong>Methacholine challenge test, N,</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dose-response slope, Mean (SD)</td>
<td>527</td>
<td>0.25 (0.09,0.41)</td>
<td>0.001</td>
<td>0.21 (0.06,0.37)</td>
<td>0.005</td>
</tr>
<tr>
<td>No AHR (reference)</td>
<td>376</td>
<td>1</td>
<td></td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>Any AR (PD&lt;sub&gt;20&lt;/sub&gt;≤4mg)‡, %</td>
<td>138</td>
<td>0.83 (0.68,1.00)</td>
<td>0.048</td>
<td>0.82 (0.66,1.02)</td>
<td>0.07</td>
</tr>
<tr>
<td>High AR (PD&lt;sub&gt;20&lt;/sub&gt;≤1mg)‡, %</td>
<td>67</td>
<td>0.70 (0.54,0.90)</td>
<td>0.006</td>
<td>0.65 (0.48,0.87)</td>
<td>0.004</td>
</tr>
</tbody>
</table>

AR: Airway responsiveness; AHR: Airway Hyper-responsiveness; CC-16: Club cell secretory protein; CI: Confidence Interval; FEV<sub>1</sub>: forced expiratory volume in 1 second; FVC: Forced Vital Capacity; GFR: Glomerular Filtration Rate; OR: Odds Ratios; PD<sub>20</sub>: 20% reduction in FEV<sub>1</sub> after methacholine challenge test (1 mg or 4 mg cumulative dose); SD: Standard Deviation;

* FEV<sub>1</sub>% predicted and FVC% predicted ranged from 0 to 1 and were obtained using Stanojevic reference equations<sup>40</sup>.

† Beta estimates (95%CI) for a unitary increase in the GFR adjusted CC-16 z-score, estimated with GEE linear regression models.
‡ Odds ratios (95%CI) for a unitary increase in the GRF adjusted CC-16 z-score, estimated with GEE logistic regressions models

All estimates are reported as unadjusted and adjusted for age, smoking status and pack-years (never smokers, ex-smokers that smoked ≤15 pack-years, ex-smokers that smoked ≥15 pack-years, current smokers with <15 pack-years and current smokers with ≥15 pack-years), blood sampling time, sex (for FEV₁/FVC, any and high AHR and AR) and height (for FEV₁/FVC)
**Figure 1.** Flow chart of the EGEA population and the participants included in the study

**Figure 2.** CC-16 according to the dose-response slope by asthmatic status

Legend: CC-16 GM level by dose-response slope (grouped in quartiles. The p-values refer to test for trend among participants who did perform the methacholine challenge test. The first bar in each group is related to participants who did not perform the test because of baseline FEV$_1$ <80% predicted or FEV$_1$ post dilution <90% of the baseline FEV$_1$. 
Serum CC-16 level is associated with asymptomatic Airway responsiveness in adults from the EGEA study

SUPPLEMENTAL DATA

METHODS

Population and protocol

The EGEA combines a case-control and family study of adult and childhood asthma (http://egeaintranet.vjf.inserm.fr/). The first EGEA survey (EGEA1) was conducted from 1991 to 1995, and the protocol and descriptive characteristics have been described elsewhere. Briefly, 388 asthmatic cases, recruited in 5 chest clinics, 1244 first-degree relatives of cases, and 415 population-based controls were recruited (total, n = 2047). A 12-year follow-up of this population was conducted from 2003 to 2007 (EGEA2) in 5 centres in France (Grenoble, Paris, Lyon, Marseille, Montpellier). Participants were contacted by postal questionnaire, and non-responders were further contacted by telephone (step 1). Among the alive cohort (n = 2002), 92% (n = 1845) completed the short self-questionnaire. Responders were invited to participate in the second phase of the study (step 2). The complete examination was mostly performed in clinical centers (n = 1316; 85.3%). However, to improve the follow-up rate, some participants were examined at home (n = 72; 4.7%) or answered questionnaires by phone (n = 78; 5.0%) or mail (n = 77; 5.0%). Finally, 77% of the alive cohort (n = 1543) completed at least a detailed questionnaire. In addition, 58 new family members where included in the study at the second survey. Written consent was obtained from all participants at both surveys. Ethical approval to carry out the study was obtained for both surveys from the relevant committees (Cochin Royal Hospital, Paris, for EGEA1, and Necker-Enfants Malades Hospital, Paris, for EGEA2). Examination procedures included a detailed questionnaire, with questions on asthma and respiratory symptoms, treatment, allergic rhinitis, active smoking, and exposure to environmental tobacco smoke. Participants had blood samples that allowed to measure total IgE in a centralized laboratory (n = 1421; 88.8%). Spirometry was performed by using a standardized protocol with similar equipment across centers according to the American Thoracic Society / European Respiratory Society guidelines to measure FEV1 (n = 1414; 88.3%). Skin prick tests to 12 aeroallergens (cat, *Dermatophagoides pteronyssinus, Blattela germanica*, olive, birch, *Parieteria judaica*, timothy grass, ragweed pollen, *Aspergillus, Cladospo- rium herbarum, Alternaria tenuis*, Cypress) were performed in 1326 participants (82.8%). Sensitization was defined by the presence of at least 1 positive skin test (mean wheal diameter ≥3 mm). Strong efforts were made to standardize all the examination procedures across centers and to minimize missing data. A
quality management approach was followed for the implementation of the EGEA2 data collection, and an International Organization for Standardization (ISO) 9001:2000 certification was obtained (http://www.afaq.org/certification5262711141114).

**Phenotype definitions**

Inhaled corticosteroid use was defined by a positive answer to the question, “Have you used inhaled corticosteroids to help your breathing at any time in the past year?” with an exhaustive list of medications available in France at the time of the study.

Participants were defined with (1) controlled asthma if all the following features were present: no more than 1 instance per week of trouble breathing (defined by the answer to “How often have you had trouble with your breathing because of your asthma in the past 3 months?”) and no asthma attack in the last 3 months (defined by the answer to “How many asthma attacks have you had in the past 3 months?”), no nocturnal symptoms (woken up because of asthma or by an attack of shortness of breath) in the last 3 months, use of short-acting β2-agonist inhalers ≤2/wk in the last 3 months, no use of oral corticosteroids in the past year, FEV₁ ≥80%predicted; (2) partly controlled asthma if 1 or 2 of these features were absent; and (3) uncontrolled asthma if ≥3 of these features were absent or if respiratory problems had caused hospital or emergency admissions in the past year or use of oral corticosteroids in the past year or ≥12 asthma attacks in the past 3 months.

**Biological phenotypes**

Serum CC-16 level was determined with latex immunoassay using a rabbit anti-CC-16 antibody (Dakopatts, Glostrup, Denmark) and purified CC-16 protein as standards (home made at the Laboratory of Toxicology Applied Pharmacology, Faculty of Medicine, Catholic University of Louvain, Belgium). When pooled normal sera is fractionated by fast protein liquid chromatography on Sephacryl S-200 (Pharmacia Biotechnology, Uppsala, Sweden), CC-16 elutes as a single component with an apparent Mr of ~16 kD, and is indistinguishable from the native protein. To avoid possible interference by complement, rheumatoid factor, or chylomicrons, the plasma samples were pretreated by heating at 56°C for 30 min and by the addition of polyethylene glycol (16%, 1:1 [vol/vol] and trichloroacetic acid (10%, 1:40 [vol/vol]). After overnight precipitation at 4°C, the samples were centrifuged (2,000x g for 10 min) and CC-16 was determined in the supernatants. All samples were analyzed in duplicate at two different dilutions. The assay has a detection limit of 0.5 ng/ml and an average analytical recovery of 95%, with the intra- and inter-assay coefficients of variation ranging from 5 to 10% \(^3\). Serum creatinine was determined with standard traceable IDMS (isotope dilution mass spectrometry traceable) assay.
Glomerular filtration rate (eGFR) was estimated using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula \(^4\) (see below) and expressed as mL/min*1.73m\(^2\):
\[
eGFR = 141 \times \min(\frac{\text{Scr}}{\kappa},1)\times \max(\frac{\text{Scr}}{\kappa},1)^{-1.209} \times 0.993^{\text{Age}} \times 1.018 [\text{if female}] \times 1.159 [\text{if black}],
\]
where Scr is the serum creatinine level (mg/dL), \(\kappa = 0.7\), if female or 0.9 if males, \(\alpha = -0.329\), if females, or \(-0.411\), if males

**RESULTS**

*Characteristics of the sample*

Participants with asthma were younger and smoked less frequently than participants without asthma. Lung function parameters were lower and AHR (PD\(_{20} \leq 4\)mg) was more frequent in participants with asthma than in those without asthma.

Among participants who performed the methacholine test (N=862), 800 (514 with asthma and 286 without) had information about their reduction in FEV1 after a provocative dose of methacholine of 4mg (PD\(_{20} < 4\)mg). 339 out of 800 (42.4%) had PD\(_{20} < 4\)mg and among those 138 (138/514=26.8) were without asthma and 201 (201/286=70.3) were with asthma. For what concern PD\(_{20} < 1\)mg, data were available for 815 participants (523 without asthma and 292 with asthma). Among those, 67 (12.8) with asthma and 162 (55.4) controls reported PD\(_{20} < 1\)mg.

Participants who performed the methacholine test were more often females (54% vs. 45%, \(p=0.007\)), were younger (mean age=41 vs. 50 years, \(p<0.001\)), smoked more frequently (24.3 % vs. 19.6%, \(p=0.06\)), had higher level of eGFR (mean value: 103 vs. 95 mL/min*1.73m\(^2\), \(p<0.001\), age and sex adjusted \(p<0.001\)) and higher FEV\(_1\) (mean value: 3.5 vs. 2.9 L, \(p<0.001\), age and sex adjusted \(p<0.001\)) than participants who did not (N=416).

**Table E1.** Association between asthma, airway responsiveness and lung function and GFR-standardized CC-16 z-score in participants with asthma

<table>
<thead>
<tr>
<th></th>
<th>N</th>
<th>Unadjusted beta/ OR (95%CI)</th>
<th>p</th>
<th>Adjusted beta/ OR (95%CI)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Lung function measurements</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV(_1) % predicted(^*,,^a)</td>
<td>791</td>
<td>1.53 (-0.21,3.27)</td>
<td>0.09</td>
<td>1.53 (-0.21,3.27)</td>
<td>0.19</td>
</tr>
<tr>
<td>FVC % predicted(^*,,^a)</td>
<td>791</td>
<td>0.44 (-0.82,1.71)</td>
<td>0.49</td>
<td>0.44 (-0.82,1.71)</td>
<td>0.67</td>
</tr>
<tr>
<td>FEV1/FVC(^a)</td>
<td>762</td>
<td>0.86 (-0.28,2.00)</td>
<td>0.14</td>
<td>0.86 (-0.28,2.00)</td>
<td>0.15</td>
</tr>
</tbody>
</table>

**Methacholine challenge test, N**
<p>| | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose-response slope*</td>
<td>300</td>
<td>0.05 (-0.16,0.26)</td>
<td>0.63</td>
<td>0.08 (-0.13,0.30)</td>
<td>0.45</td>
</tr>
<tr>
<td>No AHR (ref)</td>
<td></td>
<td>85</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any AHR (PD20≤4mg)b, %</td>
<td>201</td>
<td>1.04 (0.78,1.39)</td>
<td>0.77</td>
<td>0.99 (0.72,1.36)</td>
<td>0.97</td>
</tr>
<tr>
<td>High AHR (PD20≤1mg)b, %</td>
<td>162</td>
<td>1.06 (0.82,1.36)</td>
<td>0.65</td>
<td>1.07 (0.81,1.41)</td>
<td>0.62</td>
</tr>
</tbody>
</table>

AR: Airway responsiveness; AHR: Airway Hyper-responsiveness; CC-16: Club cell secretory protein; CI: Confidence Interval; FEV1: forced expiratory volume in 1 second; FVC: Forced Vital Capacity; GFR: Glomerular Filtration Rate; GM: Geometric Mean; OR: Odds Ratios; PD20: 20% reduction in FEV1 after methacholine challenge test (1 mg or 4 mg cumulative dose); SD: Standard Deviation;

* FEV1% predicted and FVC% predicted ranged from 0 to 1 and were obtained using Quanjer reference equations

* Beta estimates (95%CI) for a unitary increase in the GRF adjusted CC-16 z-score, estimated with GEE linear regression models

* Odds ratios (95%CI) for a unitary increase in the GRF adjusted CC-16 z-score, estimated with GEE logistic regressions models

All estimates are reported as unadjusted and adjusted for age, smoking status and pack-years (never smokers, ex-smokers that smoked ≤15 pack-years, ex-smokers that smoked ≥15 pack-years, current smokers with <15 pack-years and current smokers with ≥15 pack-years), blood sampling time, sex (for FEV1/FVC, any and high AHR and AR) and height (for FEV1/FVC)
Figure E1. Association between lung function, AR and GFR-standardized CC-16 z-score grouped in quartiles in participants without asthma
Legend: prevalence of AHR and degree of AR by quartiles of CC-16 z-score. Asterisks represent P-values obtained by comparing the odds ratio of 

![Graph showing lung function parameters and dose-response slope](image)
having AHR (Any AHR (PD_{20} ≤ 4mg) or High AHR (PD_{20} ≤ 1mg)) or the average degree of AR, for each quartile of CC-16 z-score, using the first quartile as reference, after adjustment for blood sampling time, sex, age and smoking status. ((*) P<0.10, (***) P<0.05, (*** P<0.001)).
**Figure E2.** Association between the dose-response slope and lung function and GFR-standardized CC-16 z-score stratified by smoking status in non-asthmatic participants.

Legend: regression coefficients (Beta) and 95%CI for the association between CC-16 z-score and Airway responsiveness, estimated through GEE logistic and linear models, stratified by smoking status and adjusted by age, sex and sampling time and height (for FEV1/FVC). The P-values refer to the interaction between smoking status and the CC-16 z-scores.
References


